World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)

03 Dec 2010 • by Natalie Aster

New York – “The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade. The top biopharmaceuticals companies not surprisingly include the same names that have dominated pharmaceuticals for years - Pfizer, Merck and Novartis. Unable to ignore the benefits of investing in biotechnology, they are focusing on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.”

Companies such as Amgen and Genzyme, which specialize in biotechnology, are now competing with a growing number of companies, and the line between pharmaceutical and biotech specialty companies is becoming blurred to the point that a distinction almost no longer exists. This trend is expected to continue to grow.

The research “World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) ” by Kalorama Information captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines) and providing estimates and forecasts for the world biopharma market.

Report Details:

World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)

Date: July 2010
Pages: 230
Price: US$ 3,995.00

Key Issues and Trends in the Industry

The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to the development and commercialization of biopharmaceuticals. The following issues are covered in the report:

  • Biotechnology Drug Development;
  • Orphan Drugs;
  • Fast Track Drug Status;
  • Other Accelerated Methods for Drug Approval;
  • Pharmaceutical Regulatory Exclusivity;
  • Biosimilar Development;
  • Aging Populations;
  • Mergers, Acquisitions, and Collaborations;
  • Contributors to R&D Success;
  • R&D Spending Trends;
  • The Role of Contract Research Organizations;
  • Sustainability in a Changing Pharmaceutical Industry.

In this comprehensive look at the pipeline of major companies, Kalorama Information presents an accurate picture of the marketplace today, including:

  • Market Estimates by Major Drug Category, including: Cardiovascular/Blood, Neurotherapeutics, Infection, Oncology, Respiratory/Inflammatory, Gastrointestinal, Other;
  • Discussion of Marketplace Trends;
  • Pipeline Analysis of Major Pharmacos;
  • Detailed Company Profiles;
  • Comparison of Market at Current Growth Versus Impact of Late-Stage Products;
  • Biopharmaceutical Market Breakdown;
  • Best-Selling Biopharmaceutical Products;
  • Regulatory Activity and Market Impact.

The top 50 companies make up over 90% of the world biopharmaceutical market, while the top three companies accounted for nearly a quarter of all global sales in 2009. Kalorama looks at each key player's late-stage pipeline in detail.

More information can be found in the report “World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) ” by Kalorama Information .

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 123 2220
Fax: +44 207 900 3970
ps@marketpublishers.com
www.marketpublishers.com